Table 2. Comparison of laboratory and imaging measurements and procedural characteristics in patients with low and high HRR.
| Variables | The low HRR group (< 0.74) (n = 226) |
The high HRR group (≥ 0.74) (n = 358) |
P-value |
| Data are presented as means ± SD or n (%). *Presented as median (interquartile range). HRR: hemoglobin-to-red cell distribution width ratio. | |||
| Laboratory parameters | |||
| Urea, mg/dL | 56 (41–73)* | 45 (36–58)* | < 0.001 |
| Creatinine, mg/dL | 1.04 (0.83–1.41)* | 0.95 (0.77–1.14)* | < 0.001 |
| Aspartate aminotransferase, U/L | 21 (16–29)* | 22 (17–30)* | 0.386 |
| Albumin, g/L | 3.8 ± 0.4 | 4.10 ± 0.4 | < 0.001 |
| Total cholesterol, mg/dL | 148 (125–175)* | 166 (139–196)* | < 0.001 |
| Low-density lipoprotein cholesterol, mg/dL | 84 (63–107)* | 96 (73–118)* | < 0.001 |
| High-density lipoprotein cholesterol, mg/dL | 40 (33–49)* | 44 (36–52)* | < 0.001 |
| Triglyceride, mg/dL | 106 (79–148)* | 114 (91–166)* | 0.005 |
| Non-high-density lipoprotein cholesterol, mg/dL | 107 (84–132)* | 120 (96–148)* | < 0.001 |
| Baseline N-terminal pro-B-type natriuretic peptide, pg/mL | 5267 (1991–11,491)* | 1979 (796–4446)* | < 0.001 |
| Baseline troponin I, ng/L | 28 (12–151)* | 24 (10–89)* | 0.097 |
| Baseline C-reaktive protein, mg/dL | 10 (2–30)* | 6 (0–12)* | < 0.001 |
| White blood cell count, × 109/L | 7.0 (5.7–8.9)* | 6.9 (5.8–8.1)* | 0.269 |
| Neutrophil count, × 109/L | 4.7 (3.6–6.3)* | 4.4 (3.5–5.3)* | 0.007 |
| Lymphocyte count, × 109/L | 1.3 (0.9–1.8)* | 1.7 (1.3–2.1)* | < 0.001 |
| Monocyte count, × 109/L | 0.5 (0.4–0.6)* | 0.4 (0.3–0.5)* | 0.020 |
| Haemoglobin, g/dL | 10.3 ± 1.3 | 12.9 ± 1.3 | < 0.001 |
| Platelets, × 109/L | 238 (188–312)* | 221 (177–267)* | < 0.001 |
| Red cell distribution width, % | 17.2 ± 2.2 | 14.4 ± 1.0 | < 0.001 |
| Mean platelet volume, fL | 8.7 ± 1.0 | 8.8 ± 1.0 | 0.217 |
| Mean corpuscular volume, fL | 84 ± 9 | 89 ± 5 | < 0.001 |
| Echocardiography | |||
| Left ventricular ejection fraction, % | 55 (42–60)* | 55 (45–60)* | 0.387 |
| Aortic valve area, cm2 | 0.7 (0.6–0.8)* | 0.7 (0.6–0.8)* | 0.083 |
| Mean gradient, mmHg | 45 (40–54)* | 46 (40–54)* | 0.176 |
| Peak velocity, m/sn | 4.3 ± 0.6 | 4.4 ± 0.6 | 0.568 |
| Moderate to severe aortic regurgitation | 73 (32%) | 148 (41%) | 0.028 |
| Moderate to severe mitral regurgitation | 135 (60%) | 186 (52%) | 0.057 |
| Moderate to severe tricuspid regurgitation | 126 (56%) | 136 (38%) | < 0.001 |
| Computed tomography | |||
| Anulus perimeter, mm | 77 ± 8 | 78 ± 9 | 0.478 |
| Anulus area, mm2 | 471 (415–522)* | 469 (406–549)* | 0.757 |
| Agatston calcium score, HU | 2611 (1715–3440)* | 2534 (1584–3770)* | 0.641 |
| Procedural and bioprosthetic valve characteristics | |||
| Transfemoral approach | 221 (98%) | 353 (99%) | 0.459 |
| Balloon predilatation | 138 (61%) | 223 (62%) | 0.734 |
| Balloon postdilatation | 56 (24%) | 102 (29%) | 0.315 |
| Valve type | 0.278 | ||
| Balloon expandable | 70 (31%) | 96 (27%) | |
| Self expanding | 156 (69%) | 262 (73%) | |